More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.42B
EPS
-3.76
P/E ratio
--
Price to sales
4.42
Dividend yield
--
Beta
2.017503
Previous close
$51.02
Today's open
$51.43
Day's range
$44.24 - $51.68
52 week range
$32.21 - $170.87
show more
CEO
Katherine Stueland
Employees
1300
Headquarters
Stamford, CT
Exchange
Nasdaq Global Select
Shares outstanding
29972493
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
GeneDx Announces Leadership Transition
GAITHERSBURG, Md.--(BUSINESS WIRE)--Everett Cunningham, veteran diagnostics and commercial leader, appointed Chief Executive Officer of GeneDx to lead next phase of growth.
Business Wire • 7 hours ago

GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.
Business Wire • Nov 11, 2026

Why GeneDx Holdings Stock Just Dropped 16.6%
GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates, but the 32,134 exome and genome results were up 25% against the 29.2% or more the company had promised.
The Motley Fool • Nov 10, 2026

GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript
GeneDx Holdings Corp. ( WGS ) Q3 2026 Earnings Call November 9, 2026 4:30 PM EST Company Participants Sabrina Dunbar - Director of Investor Relations & Communications Katherine Stueland - CEO & Director Mark Gardner - President Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division David Westenberg - Piper Sandler & Co., Research Division Tycho Peterson - Jefferies LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 10, 2026

GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.
Business Wire • Nov 10, 2026

4 Post-Earnings Losers Drawing Unusual Options Volume
Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (NASDAQ:APPS) all suffering double-digit losses today.
Schaeffers Research • Nov 10, 2026

GeneDx Q3 Earnings Call Highlights
GeneDx NASDAQ: WGS reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its expectations for test volume growth.
MarketBeat • Nov 10, 2026

GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability
GeneDx Holdings is transitioning to sustained profitability, with strong revenue growth expected through 2027. WGS beat revenue estimates for Q3 but fell short on EPS estimates. Key strategies include optimizing reimbursement rates, operational efficiencies, and leveraging AI to enhance billing and payment reliability.
Seeking Alpha • Nov 10, 2026

GeneDx Reports Third Quarter 2026 Financial Results
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.
Business Wire • Nov 9, 2026

GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.49 per share a year ago.
Zacks Investment Research • Nov 10, 2026

¹ Disclosures

Open an M1 investment account to buy and sell GeneDx Holdings Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.